Potential for Treating HIV Lipodystrophy with Tesamorelin

by | Jul 4, 2022 | Research

Tesamorelin peptide is the synthetic equivalent of the growth hormone-releasing hormone (GHRH), which helps treat HIV-induced Lipodystrophy — a metabolic condition featured by fat redistribution, insulin resistance, and hyperlipidemia following antiretroviral HIV infection therapy. It functions to improve abdominal weight loss, the ability to create human-growth hormones naturally, cognitive function, and metabolism.

Tesamorelin, the synthetic equivalent of GHRH, mimics all the functions of the naturally occurring GHRH and GHRH analogs such as GRF (1-29), Sermorelin, CJC-1295, etc. Tesamorelin peptide combination with trans-3-hexanoic acid makes Tesamorelin peptide stable in human plasma and enhances its half-life. Tesamorelin peptide also functions to preserve the physiological action of GHRH with fewer side effects compared to similar molecules that erase the pulsatile release of the growth hormone.

The Benefits/Effects of Tesamorelin Peptide

The Effects of Tesamorelin Peptide on Lipodystrophy

Tesamorelin peptide primarily treats HIV-induced lipodystrophy and antiretroviral treatment’s side effects. Lipodystrophy is associated with fat buildup in the belly and other areas of the body. Protease inhibitors, according to scientists, play a vital role in the pathophysiology of lipodystrophy.

Lipodystrophy patients rely on diet, exercise, and a plethora of useless drugs. Surgery is recommended if these do not work, which can be risky in most circumstances. The FDA licensed Tesamorelin in 2010 for the treatment of HIV-induced lipodystrophy.

According to research, Tesamorelin peptide reduces fat accumulation by around 20% and is four times more powerful than other known treatments combined.

The Effect of Tesamorelin on Growth Hormone Deficient and HIV Patients

According to researchers, Highly Active Antiretroviral Therapy (HAART)—the regimen for treating and maintaining HIV-1—is linked to several metabolic and endocrine issues, including growth hormone insufficiency. The pituitary gland is damaged during HIV infection, resulting in growth hormone deficit in approximately one-third of HIV patients on HAART. According to research, Tesamorelin peptide is a more effective and safer way of boosting Growth Hormone levels than exogenous GH injection, particularly in HIV patients.

The Role of Tesamorelin Peptide in Cardiac Diseases

Individuals living with HIV have weakened immune systems, making them vulnerable to many infections, including an increased risk of cardiovascular disease (CVD). For many years, the only approach to extending a patients lifespan or prolonging life in HIV patients was to prevent heart disease. Recently, statins have been used in treating and the medical care of HIV patients.

Tesamorelin peptide studies prove to lower triglyceride levels, non-HDL-C levels, and cholesterol levels in HIV patients. It also indicates a 15% reduction in visceral adipose tissues.

It is critical to recognize that inflammation can cause ectopic fat accumulation following lipodystrophy. Inflammation is a risk factor for cardiovascular disease. The presence of liver fat, epicardial fat, and visceral adipose tissues are associated with an elevated risk of heart disease. Tesamorelin peptide decreases inflammation and the risk of heart disease by reducing ectopic fat accumulation.

The Role of Tesamorelin in Peripheral Nerve Damages

Peripheral nerve damage can occur due to an accident, surgical intervention, or diabetes. Damage to the peripheral nerves frequently results in critical issues with sensory and motor capabilities in the afflicted area. If this is the case, little can be done because fact nerve cells are almost impossible to repair. Nonetheless, experts believe that medicines based on growth hormone regulation may improve peripheral nerve damage and the degree and rate of repair. Tesamorelin peptide is undergoing research to determine if it is the best option for intervention.

The Effect of Tesamorelin Peptide on Dementia

Dementia is a progressive or chronic illness that causes cognitive ability to decrease with age. It is distinguished by impairment of at least two brain functions, specifically memory loss and judgment.

Tesamorelin peptide in studies proves to improve memory in people with early-stage dementia. Tesamorelin peptide and other GHRH analogs may influence dementia by boosting gamma-aminobutyric acid (GABA) levels in the brain and decreasing Myo-inositol (MI) levels, according to twenty-week research at the University of Washington School of Medicine. These findings imply that Tesamorelin might be used to treat dementia.

The Adverse Effects of Tesamorelin Peptide

Although the administration of Tesamorelin peptide is safe. It also exhibits mild adverse effects. Some of which are:

  • Vomiting or nausea
  • Injury-related swelling, redness, or irritation
  • Muscle aches and pains
  • Sweating as well as
  • Itching is minimal

Scientists believe that Tesamorelin peptides can react with certain types of medications.


There are robust benefits associated with Tesamorelin peptides. However, it is vital to note that Tesamorelin is a research chemical/peptide, limited to educational and scientific purposes. Not for human consumption or use.

Despite the robust benefits associated with Pralmorelin, it is vital to note that it is a research peptide, limited to educational and scientific purposes—not for human consumption. Disclaimer: The products mentioned are not for human or animal consumption. All the information shared in this article is for educational purposes only.

Disclaimer: The products mentioned are not for human or animal consumption. All the information shared in this article is for educational purposes only.